OTC · Biotechnology

Amplia Therapeutics Limited (INNMF) Stock

$0.11 +0.00% OTC: INNMF Healthcare

Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases.

Valuation

MetricValue
Price$0.11
Market Cap$56.46M
P/E Ratio-8.38
P/B Ratio1.82
P/S Ratio0.00
EPS (TTM)$-0.02
52-Week High$0.27
52-Week Low$0.05
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-18.71%
ROA-18.60%
ROCE-33.14%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio19.78

Annual Financials (USD)

Metric20222023202420252026
Revenue$2.0M$1.0M$4.0M$4.0M$0
Operating Profit$-4.0M$-6.0M$-4.0M$-7.0M$-13.0M
Net Profit$-4.0M$-6.0M$-5.0M$-7.0M$-8.0M
EPS$-0.02$-0.03$-0.02$-0.02$-0.02
Op Margin-183.7%-520.3%-99.4%-172.2%—

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$24.0M$19.0M$15.0M$23.0M$42.0M
Total Liabilities$3.0M$3.0M$3.0M$2.0M$2.0M
Cash$15.0M$9.0M$3.0M$11.0M$28.0M
Borrowings$2.0M$2.0M$2.0M$0$0

Latest News

Amplia Announces Publication of New FAK Inhibitor Patent Application GlobeNewswire · Jul 9, 2026 Amplia Announces Appointment of Brett Carter to Board GlobeNewswire · Jul 7, 2026 Amplia Announces Changes to Board’s Leadership Roles GlobeNewswire · Jul 6, 2026 Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer GlobeNewswire · Jun 22, 2026 INNMF Advancing Cancer Treatments Zacks Small Cap Research · Jun 5, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-4.0M$-5.0M$-5.0M$-7.0M$-9.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$14.0M$0$0$-1.0M$0
Net Cash Flow$13.0M$-5.0M$-6.0M$7.0M$18.0M
Free Cash Flow$-4.0M$-5.0M$-5.0M$-7.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.34
EV / EBITDA-3.44
FCF Yield-12.20%
Quick Ratio19.78
Interest Coverage-758.70
Return 1Y-45.00%
Return 3Y83.33%
Return 5Y—

Ownership

Insiders Held9.56%
Institutions Held22.97%
Institutions Float Held25.40%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHFFArch Biopartners Inc. $0.61 +0.80% -22.19 $41.10M 0.00%
CLTEFClara Technologies Corp. $0.06 -91.43% -23.94 $3.60M 0.00%
CVALFCovalon Technologies Ltd. $1.54 +0.00% 36.52 $42.53M 6.88%
CYYNFCynata Therapeutics Limited $0.00 — -0.33 $973817 0.00%
HBPCFHelix BioPharma Corp. $1.71 +0.00% -32.27 $130.61M 0.00%

About Amplia Therapeutics Limited

Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases. Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions. Another compound, AMP886, is also under development for potential applications in cancer and fibrotic disorders. Amplia Therapeutics maintains a strategic collaboration with the Garvan Institute of Medical Research in Sydney, and the company adopted its current name in September 2018, having previously operated as Innate Immunotherapeutics Limited.

Amplia Therapeutics Limited is headquartered in AU.

Amplia Therapeutics Limited (INNMF) stock trades at $0.11 with a market capitalization of $56.46M. The stock is valued at a price-to-earnings (P/E) ratio of -8.38, price-to-book of 1.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.05 and $0.27, and currently trades 59.3% below its 52-week high.

On profitability, Amplia Therapeutics Limited generates a return on equity (ROE) of -18.71%, return on capital employed of -33.14%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.ampliatx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides